No Data
No Data
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the
BTIG Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $70
BTIG analyst Kaveri Pohlman maintains $Arcus Biosciences(RCUS.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 25.8% and a to
Express News | Arcus Biosciences Inc: No Unexpected Safety Signals Were Observed at Time of Data Cutoff, March 12, 2024
Express News | Arcus Biosciences Inc: Domvanalimab Plus Zimberelimab and Chemotherapy Regimen Was Generally Well Tolerated
Express News | Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper Gi Cancers
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.